Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 20/20 | 0.61 |
| ▸ | JAK3 | P52333 | 20/20 | 0.61 |
| ▸ | JAK2 | O60674 | 11/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.60 |
| ▸ | SYK | P43405 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | TYK2 | P29597 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL29358806 | 1.00 | JAK1 (0.61) | JAK1JAK3JAK2CYP3A4SYK | |
| Trifluoroacetic Acid SCHEMBL29360159 | 0.94 | JAK1 (0.61) | JAK1JAK3JAK2CYP3A4SYK | |
| Trifluoroacetic Acid SCHEMBL524459 | 0.94 | JAK1 (0.61) | JAK1JAK3JAK2CYP3A4SYK | |
| SCHEMBL23356201 | 0.93 | JAK1 (0.68) | JAK1JAK3JAK2CYP3A4SYK | |
| Trifluoroacetic Acid SCHEMBL29355568 | 0.88 | JAK1 (0.64) | JAK1JAK3JAK2CYP3A4SYK | |
| Trifluoroacetic Acid SCHEMBL524980 | 0.88 | JAK1 (0.64) | JAK1JAK3JAK2CYP3A4SYK | |
| Trifluoroacetic Acid SCHEMBL525133 | 0.87 | JAK3 (0.51) | JAK1JAK3JAK2CYP3A4SYK | |
| Trifluoroacetic Acid SCHEMBL29360364 | 0.87 | JAK3 (0.51) | JAK1JAK3JAK2CYP3A4SYK | |
| SCHEMBL23356150 | 0.86 | JAK1 (0.69) | JAK1JAK3JAK2CYP3A4SYK | |
| Trifluoroacetic Acid SCHEMBL29359263 | 0.86 | JAK1 (0.60) | JAK1JAK3JAK2CYP3A4SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2598500-B1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS INC (US) | 2021-05-19 | — | — | EP | claimed |
| EP-2598500-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | Rigel Pharmaceuticals, Inc. (US) | 2013-06-05 | — | — | EP | claimed |
| US-20130090310-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2013-04-11 | — | — | US | claimed |
| US-20120028923-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2012-02-02 | — | — | US | claimed |
| WO-2012015972-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | WO | claimed |
| US-20220024907-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2022-01-27 | — | — | US | disclosed |
| US-11174251-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| EP-2598500-B1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS INC (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20200115371-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2020-04-16 | — | — | US | disclosed |
| US-10479783-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2019-11-19 | — | — | US | disclosed |
| US-RE47396-E1 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-20180162848-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20150259332-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2015-09-17 | — | — | US | disclosed |
| US-9067925-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20130310340-A1 | METHOD OF TREATING MUSCULAR DEGRADATION | RIGEL PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| EP-2598500-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | Rigel Pharmaceuticals, Inc. (US) | 2013-06-05 | — | — | EP | disclosed |
| US-20130090310-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-8343954-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120028923-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2012-02-02 | — | — | US | disclosed |
| WO-2012015972-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115371-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | JAK1 3/4885JAK3 1/4885JAK2 2/4885 |
| US-20180162848-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | JAK1 3/4885JAK3 1/4885JAK2 2/4885 |
| US-20130310340-A1 | METHOD OF TREATING MUSCULAR DEGRADATION | PYGM, CKMT1A; CKMT1B, SMN1; SMN2 | JAK1 4796/4885JAK3 4792/4885JAK2 4729/4885 |
| US-20150259332-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | JAK1 3/4885JAK3 1/4885JAK2 2/4885 |
| US-11174251-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | JAK1 3/4885JAK3 1/4885JAK2 2/4885 |
| US-20120028923-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | JAK1 3/4885JAK3 1/4885JAK2 2/4885 |
| US-10479783-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | JAK1 3/4885JAK3 1/4885JAK2 2/4885 |
| US-20130090310-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | JAK1 3/4885JAK3 1/4885JAK2 2/4885 |
| US-20220024907-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | JAK1 3/4885JAK3 1/4885JAK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.